Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus

• Published in: International journal of rheumatic diseases 2014-09, Vol.17 (7), p.790-795
• Main Authors: Tselios, Konstantinos, Sarantopoulos, Alexandros, Gkougkourelas, Ioannis, Papagianni, Aikaterini, Boura, Panagiota
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; cyclophosphamide; Cyclophosphamide - administration & dosage; Female; Forkhead Transcription Factors - blood; Humans; Immunologic Factors - administration & dosage; Interleukin-2 Receptor alpha Subunit - blood; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - drug therapy; Lupus Erythematosus, Systemic - immunology; Lupus Nephritis - blood; Lupus Nephritis - diagnosis; Lupus Nephritis - drug therapy; Lupus Nephritis - immunology; Lupus Vasculitis, Central Nervous System - blood; Lupus Vasculitis, Central Nervous System - diagnosis; Lupus Vasculitis, Central Nervous System - drug therapy; Lupus Vasculitis, Central Nervous System - immunology; Male; Pulse Therapy, Drug; Remission Induction; systemic lupus erythematosus; T regulatory cells; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - immunology; Time Factors; Treatment Outcome; Up-Regulation
• ISSN: 1756-1841; 1756-185X
• DOI: 10.1111/1756-185X.12500

Background Cyclophosphamide efficacy in lupus nephritis (LN) and neuropsychiatric systemic lupus erythematosus (NPSLE) is probably mediated by a non‐specific ablation of reactive lymphocytes. However, little is known in regard to its effect on T regulatory cells (Tregs) in such patients, which was the aim of this study. Patients and Methods Ten Caucasian lupus patients were included, six with LN classes IV–V (mean age 33.8 ± 8.8 years) and four with NPSLE (mean age 35.5 ± 8.8 years, clinical manifestations: 1/4 acute confusional state, 1/4 psychosis, 2/4 refractory seizures). Cyclophosphamide was administered at monthly pulses (500 mg/m2/month for 6 months); doses of other administered drugs, including steroids, remained stable or lower. CD4+CD25highFOXP3+ Tregs were assessed by flow‐cytometry at baseline and before every subsequent pulse and 3–6 months after the final pulse. Disease activity was assessed by SLE Disease Activity Index (SLEDAI). Results In LN patients, Tregs were significantly increased even after the fourth pulse (0.54 ± 0.20% vs. 1.24 ± 0.29%, P